| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
84.65(B) |
| Last
Volume: |
3,579,101 |
Avg
Vol: |
8,731,484 |
| 52
Week Range: |
$64.58 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dickinson Andrew D |
EVP, Chief Financial OfficerOf |
• – – |
2019-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,927 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-01 |
4 |
S |
$64.52 |
$258,099 |
D/D |
(4,000) |
19,921 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-01 |
4 |
OE |
$16.89 |
$40,536 |
D/D |
2,400 |
23,921 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-10-28 |
4 |
S |
$63.31 |
$359,412 |
D/D |
(5,677) |
21,521 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2019-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,527 |
64,859 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2019-08-28 |
4 |
S |
$63.91 |
$313,671 |
D/D |
(4,908) |
97,854 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2019-08-28 |
4 |
OE |
$23.76 |
$116,590 |
D/D |
4,908 |
102,762 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-08-19 |
4 |
S |
$64.35 |
$39,123 |
D/D |
(608) |
27,198 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-08-10 |
4 |
D |
$65.24 |
$30,141 |
D/D |
(462) |
27,806 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,070 |
28,268 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-07-23 |
4 |
AS |
$65.07 |
$468,504 |
D/D |
(7,200) |
27,198 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-07-23 |
4 |
OE |
$24.91 |
$179,316 |
D/D |
7,200 |
34,398 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-06-18 |
4 |
AS |
$68.75 |
$399,850 |
D/D |
(5,816) |
27,198 |
|
- |
|
| Hamill Laura |
EVP, Worldwide Commercial Ops |
• • – |
2019-05-08 |
4 |
D |
$66.07 |
$231,245 |
D/D |
(3,500) |
6,340 |
|
- |
|
| Hamill Laura |
EVP, Worldwide Commercial Ops |
• • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,840 |
9,840 |
|
- |
|
| Manwani Harish |
Director |
• • – |
2019-05-07 |
4 |
D |
$66.40 |
$27,622 |
D/D |
(416) |
1,867 |
|
- |
|
| Manwani Harish |
Director |
• • – |
2019-05-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,283 |
2,283 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2019-05-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,283 |
126,782 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2019-05-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,283 |
97,854 |
|
- |
|
| Whitley Richard James |
Director |
• • – |
2019-05-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,283 |
27,418 |
|
- |
|
| Whitley Richard James |
Director |
• • – |
2019-05-01 |
4 |
AS |
$65.02 |
$619,934 |
D/D |
(9,534) |
25,135 |
|
- |
|
| Whitley Richard James |
Director |
• • – |
2019-05-01 |
4 |
OE |
$22.02 |
$209,891 |
D/D |
9,534 |
34,669 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2019-05-01 |
4 |
AS |
$64.89 |
$186,116 |
D/D |
(2,868) |
54,860 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2019-05-01 |
4 |
OE |
$22.02 |
$63,139 |
D/D |
2,868 |
57,728 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2019-04-24 |
4 |
OE |
$24.91 |
$328,945 |
D/D |
13,208 |
43,332 |
|
- |
|
2499 Records found
|
|
Page 16 of 100 |
|
|
0.14 (0.21%) 
